This article was originally published in The Gray Sheet
July 15 premarket update discussion with FDA topsiders will address such issues as in vitro diagnostics classification/reclassification, new IVD guidance documents, and changes in the 510(k) program - including abbreviated, special, and exempted 510(k)s. The conference will conclude by addressing several emerging premarket issues including modular premarket approval review, product development protocols and recognition of standards. FDA Office of Device Evaluation Director Susan Alpert and Division of Clinical Laboratory Devices Director Steve Gutman are among the agency personnel scheduled to speak. The conference will be held between 1:00 PM and 3:30 PM eastern standard time. For further information, call 800/956-6293
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.